US 2026/0152552 A1 · NOVEL ANTI-L1CAM ANTIBODY

Abstract

The invention provides a fully humanized monoclonal antibody which binds to a human L1CAM with a high specificity, an antigen-binding fragment thereof, a bispecific antibody thereof, etc. The antibodies of the present invention can be used in the diagnosis and treatment of cancer.

Claims44

Dependent claims

An antibody or antigen binding fragment thereof specifically binding to L1CAM comprising heavy chain and light chain CDRs selected from the following groups:

(a) a HCDR1 comprising the amino acid sequence of SEQ ID NO:
19 or 25, a HCDR2 comprising the amino acid sequence of SEQ ID NO:
20, a HCDR3 comprising the amino acid sequence of SEQ ID NO:
21 or 27, a LCDR1 comprising the amino acid sequence of SEQ ID NO:
22, a LCDR2 comprising the amino acid sequence of SEQ ID NO:
23, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:
24;
(b) a HCDR1, HCDR2, HCDR3 comprising the amino acid sequence of SEQ ID NO:
1, 2 and 3, respectively, and a LCDR1, LCDR2 and LCDR3 comprising the amino acid sequence of SEQ ID NO:
4, 5 and 6, respectively;
(c) a HCDR1, HCDR2, HCDR3 comprising the amino acid sequence of SEQ ID NO:
7, 8 and 9, respectively, and a LCDR1, LCDR2 and LCDR3 comprising the amino acid sequence of SEQ ID NO:
10, 11 and 12, respectively;
(d) a HCDR1, HCDR2, HCDR3 comprising the amino acid sequence of SEQ ID NO:
13, 14 and 15, respectively, and a LCDR1, LCDR2 and LCDR3 comprising the amino acid sequence of SEQ ID NO:
10, 11 and 12, respectively;
and
(e) a HCDR1, HCDR2, HCDR3 comprising the amino acid sequence of SEQ ID NO:
37, 38 and 39, respectively, and a LCDR1, LCDR2 and LCDR3 comprising the amino acid sequence of SEQ ID NO:
40, 41 and 42, respectively.

17 more elements

Dependencies are inferred from the claim text.

Facts

Application

18/706,348Filed 1 Nov 2022

Priority

CN 202111296133.43 Nov 2021

Published

4 Jun 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification19 codes

A61P 35/00
Antineoplastic agents
C07K 16/2803
Against receptors, cell surface antigens or cell surface determinants: against the immunoglobulin superfamily
A61K 38/00
Medicinal preparations containing peptides
A61K 47/68
The non-active ingredient being a modifying agent: the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment

Abstract

Claims44

Dependent claims

An antibody or antigen binding fragment thereof specifically binding to L1CAM comprising heavy chain and light chain CDRs selected from the following groups:

(a) a HCDR1 comprising the amino acid sequence of SEQ ID NO:
19 or 25, a HCDR2 comprising the amino acid sequence of SEQ ID NO:
20, a HCDR3 comprising the amino acid sequence of SEQ ID NO:
21 or 27, a LCDR1 comprising the amino acid sequence of SEQ ID NO:
22, a LCDR2 comprising the amino acid sequence of SEQ ID NO:
23, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:
24;
(b) a HCDR1, HCDR2, HCDR3 comprising the amino acid sequence of SEQ ID NO:
1, 2 and 3, respectively, and a LCDR1, LCDR2 and LCDR3 comprising the amino acid sequence of SEQ ID NO:
4, 5 and 6, respectively;
(c) a HCDR1, HCDR2, HCDR3 comprising the amino acid sequence of SEQ ID NO:
7, 8 and 9, respectively, and a LCDR1, LCDR2 and LCDR3 comprising the amino acid sequence of SEQ ID NO:
10, 11 and 12, respectively;
(d) a HCDR1, HCDR2, HCDR3 comprising the amino acid sequence of SEQ ID NO:
13, 14 and 15, respectively, and a LCDR1, LCDR2 and LCDR3 comprising the amino acid sequence of SEQ ID NO:
10, 11 and 12, respectively;
and
(e) a HCDR1, HCDR2, HCDR3 comprising the amino acid sequence of SEQ ID NO:
37, 38 and 39, respectively, and a LCDR1, LCDR2 and LCDR3 comprising the amino acid sequence of SEQ ID NO:
40, 41 and 42, respectively.

17 more elements

Dependencies are inferred from the claim text.

Novel anti-l1cam antibody

Life of this patent

Abstract

Claims44

Novel anti-l1cam antibody

Life of this patent

Abstract

Claims44